Millennium Management’s Regenxbio RGNX Stock Holding History

Millennium Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,000	Closed	-$680K	–	6425
2020 Q4	$680K	Buy	+15,000	New	+$524K	﹤0.01%	3977

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's RGNX Position: Q1 2026 in Review

Millennium Management increased its Regenxbio (RGNX) stake by 33% in Q1 2026, buying an estimated $741K and bringing the position to 285,174 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Millennium Management first reported a position in RGNX in Q3 2015 and has held it in 36 quarters since. The position peaked at $14.3M in Q1 2017. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Millennium Management held 285,174 shares of Regenxbio worth $2.39M as of Q1 2026.
Millennium Management bought 70,508 Regenxbio shares in Q1 2026, an estimated $741K.
Regenxbio made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3704 holding.
Millennium Management first reported a position in Regenxbio in Q3 2015 and has held it in 36 quarters since.
Millennium Management's Regenxbio position peaked at $14.3M in Q1 2017.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.